Gabriel Étienne
Impact in
- Hematology top 0.05%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 135
- Chronic Myeloid Leukemia Treatments 124
- Acute Myeloid Leukemia Research 16
- Genetics 118
- Chronic Lymphocytic Leukemia Research 91
- Myeloproliferative Neoplasms: Diagnosis and Treatment 30
- Co-authors
- François‐Xavier Mahon (50 shared papers)Josy J. Reiffers (8 shared papers)Timothy P. Hughes (11 shared papers)Andreas Hochhaus (9 shared papers)Giuseppe Saglio (7 shared papers)Richard A. Larson (7 shared papers)Delphine Réa (32 shared papers)Richard E. Clark (5 shared papers)
- Journals
- Blood (70 papers)Haematologica (12 papers)Leukemia (10 papers)British Journal of Haematology (10 papers)Journal of Clinical Oncology (5 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Gabriel Étienne
159 papers receiving 10.9k citations
Gabriel Étienne's Hit Papers
Peers
Comparison fields: 5 of 110
- Hematology 9.0k
- Genetics 6.5k
- Rheumatology 3.4k
- Oncology 1.5k
- Pathology and Forensic Medicine 856
Countries citing papers authored by Gabriel Étienne
This map shows the geographic impact of Gabriel Étienne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Étienne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Étienne more than expected).
Fields of papers citing papers by Gabriel Étienne
This network shows the impact of papers produced by Gabriel Étienne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Étienne. The network helps show where Gabriel Étienne may publish in the future.
Co-authors
The 25 scholars most cited alongside Gabriel Étienne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 165 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia Hit paper breakdown → | 2010 | 1381 |
| 2 | Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Hit paper breakdown → | 2010 | 1264 |
| 3 | Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial Hit paper breakdown → | 2016 | 669 |
| 4 | 2006 | 518 | |
| 5 | Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Hit paper breakdown → | 2018 | 481 |
| 6 | Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia Hit paper breakdown → | 2016 | 394 |
| 7 | 2012 | 361 | |
| 8 | 2012 | 360 | |
| 9 | 2013 | 356 | |
| 10 | 2010 | 316 | |
| 11 | 2018 | 299 | |
| 12 | 2008 | 296 | |
| 13 | 2014 | 293 | |
| 14 | 2016 | 271 | |
| 15 | Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis Hit paper breakdown → | 2021 | 247 |
| 16 | 2016 | 227 | |
| 17 | 2008 | 201 | |
| 18 | 2008 | 184 | |
| 19 | 2017 | 133 | |
| 20 | 2015 | 121 |
About Gabriel Étienne
Gabriel Étienne is a scholar working on Hematology, Genetics, Rheumatology, Immunology and Public Health, Environmental and Occupational Health, having authored 165 papers that have together received 11.1k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (124 papers), Chronic Lymphocytic Leukemia Research (91 papers), Eosinophilic Disorders and Syndromes (55 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (30 papers), Acute Myeloid Leukemia Research (16 papers), Acute Lymphoblastic Leukemia research (13 papers), Lymphoma Diagnosis and Treatment (9 papers) and Complement system in diseases (6 papers). The work is most often cited by research in Hematology (9.0k citations), Genetics (6.5k citations), Rheumatology (3.4k citations), Oncology (1.5k citations) and Pathology and Forensic Medicine (856 citations). Gabriel Étienne has collaborated with scholars based in France, United States and Italy. Frequent co-authors include François‐Xavier Mahon, Josy J. Reiffers, Timothy P. Hughes, Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson, Delphine Réa, Richard E. Clark, Laurence Legros and Françoise Huguet. Their work appears in journals such as Blood, Haematologica, Leukemia, British Journal of Haematology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.